← Back to Home

Sensorion

Euronext Growth Paris: ALSEN ↗$0.23 EUR~$150M (EUR) MCAP
#Sudden Sensorineural Hearing Loss (SSNHL)#Age-Related Hearing Loss (Presbycusis)#Ototoxicity Prevention#Cisplatin-Induced Hearing Loss#Otoferlin Gene Therapy (DFNB9)

Sensorion is a French clinical-stage biotechnology company specializing in the development of novel therapies for hearing loss disorders, including sudden sensorineural, age-related, and ototoxicity-induced hearing loss. Its pipeline combines small-molecule inner ear therapeutics with gene therapy approaches.

Company Info

Sector:Biotechnology / Hearing Loss
Headquarters:Montpellier, France
Founded:2009
Website:www.sensorion.com/

Upcoming Milestones & Key Dates

Q3 2026
Clinical Trial

SENS-501 Audiogene Phase 1/2 pediatric data update

H2 2026
Pipeline Strategy

Strategic decision on SENS-401 program following hearing loss program review

Clinical Development Pipeline

SENS-401 (arazasetron)

Target: 5-HT3 receptor antagonist / oxidative stress pathway
Sudden sensorineural hearing loss (SSNHL) - NOTA and RAU programs
Preclinical
Phase 1
Phase 2
Phase 3
Approved

SENS-501 (OTOF-GT)

Target: AAV-based gene therapy delivering OTOF gene
DFNB9 otoferlin-related hearing loss (congenital deafness)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

GJB2-GT

Target: AAV-based gene therapy delivering GJB2 (Connexin 26)
GJB2-related hearing loss (most common genetic hearing loss)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Nawal Ouzren

Chief Executive Officer

Dr. Géraldine Honnet

Chief Medical Officer

Dr. Aurélie de Pommerol

Chief Scientific Officer

Careers & Job Openings

See all open roles

Multiple Departments
See careers page
Apply Now →